HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Holger N Lode Selected Research

dinutuximab

4/2022Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.
1/2022First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma.
1/2021Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
1/2021GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
10/2020Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.
1/2020Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
1/2020Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
1/2019Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
12/2018Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
10/2018Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Holger N Lode Research Topics

Disease

47Neuroblastoma
04/2022 - 01/2003
42Neoplasms (Cancer)
06/2022 - 09/2002
14Neoplasm Metastasis (Metastasis)
10/2019 - 01/2003
3Pain (Aches)
12/2018 - 01/2018
3Leukemia
08/2009 - 07/2003
2Glioblastoma (Glioblastoma Multiforme)
06/2022 - 03/2017
2Ewing Sarcoma (Sarcoma, Ewing)
01/2022 - 01/2019
2Sarcoma (Soft Tissue Sarcoma)
01/2022 - 05/2006
2Sexually Transmitted Diseases (Sexually Transmitted Disease)
01/2018 - 01/2016
2Carcinoma (Carcinomatosis)
10/2015 - 09/2002
1Mitochondrial Diseases (Mitochondrial Disease)
06/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2022
1Hemorrhage
08/2019
1Heart Failure
12/2018
1Pulmonary Fibrosis (Fibrosing Alveolitis)
12/2018
1Hypersensitivity (Allergy)
12/2018
1Pulmonary Hypertension
12/2018
1Infections
12/2018
1Capillary Leak Syndrome
12/2018
1Mycoses (Diseases, Fungus)
12/2018
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
12/2018
1Fever (Fevers)
12/2018
1Disease Progression
10/2017
1Brain Neoplasms (Brain Tumor)
03/2017
1Septic Shock (Toxic Shock Syndrome)
08/2016
1Fournier Gangrene
08/2016
1Agranulocytosis (Granulocytopenia)
08/2016

Drug/Important Bio-Agent (IBA)

23dinutuximabIBA
04/2022 - 07/2005
11Interleukin-2 (IL2)IBA
01/2021 - 01/2004
10DNA (Deoxyribonucleic Acid)IBA
01/2018 - 12/2004
8AntigensIBA
01/2022 - 12/2004
8DNA VaccinesIBA
01/2018 - 01/2003
7CytokinesIBA
01/2021 - 03/2007
7VaccinesIBA
01/2018 - 01/2003
5Peptides (Polypeptides)IBA
10/2015 - 12/2004
4Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA
01/2018 - 12/2004
4Pharmaceutical PreparationsIBA
10/2017 - 07/2003
4Proteins (Proteins, Gene)FDA Link
01/2016 - 01/2003
4ProdrugsIBA
02/2004 - 09/2002
3Surface Antigens (Surface Antigen)IBA
01/2021 - 01/2012
3EnzymesIBA
01/2019 - 02/2003
3Monoclonal AntibodiesIBA
12/2018 - 12/2013
3Messenger RNA (mRNA)IBA
10/2015 - 05/2012
3SurvivinIBA
05/2013 - 01/2008
2Chimeric Antigen ReceptorsIBA
01/2022 - 01/2019
2Complement System Proteins (Complement)IBA
01/2021 - 07/2005
2AntibodiesIBA
01/2021 - 06/2013
2Immunoglobulin G (IgG)IBA
01/2021 - 01/2016
2GD2 gangliosideIBA
01/2019 - 03/2007
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2018 - 08/2016
2Morphine (MS Contin)FDA LinkGeneric
10/2018 - 01/2018
2ganglidiomabIBA
12/2013 - 06/2013
2Chemokine CX3CL1IBA
03/2007 - 10/2005
2lorukafusp alfaIBA
07/2004 - 01/2004
2Etoposide (VP 16)FDA LinkGeneric
07/2003 - 09/2002
1Cyclin-Dependent Kinases (cdk Proteins)IBA
06/2022
1Arginine (L-Arginine)FDA Link
06/2022
1arginine deiminaseIBA
06/2022
1Adenosine Monophosphate (AMP)IBA
06/2022
1Immunoglobulin Fc FragmentsIBA
01/2021
1Fluorouracil (Carac)FDA LinkGeneric
10/2020
1Interleukin-4 (Interleukin 4)IBA
10/2020
1Interleukin-8 (Interleukin 8)IBA
10/2020
1Blood Coagulation Factors (Coagulation Factor)IBA
08/2019
1Enhancer of Zeste Homolog 2 ProteinIBA
01/2019
1Interleukin-15 (Interleukin 15)IBA
01/2018
1Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2018
1Cell-Free Nucleic AcidsIBA
10/2017
1AndrogensIBA
03/2017
1Temozolomide (Temodar)FDA LinkGeneric
03/2017
1Aromatase InhibitorsIBA
03/2017
1Hormones (Hormone)IBA
03/2017
1Letrozole (Femara)FDA LinkGeneric
03/2017
1Aromatase (CYP19)IBA
03/2017
1LigandsIBA
01/2017
1Dipyrone (Metamizole)IBA
08/2016
1Macrophage Colony-Stimulating FactorIBA
08/2016
1Biliverdine (Biliverdin)IBA
04/2016
1Heme Oxygenase-1IBA
04/2016
1Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA
04/2016
1Heme (Haem)IBA
04/2016
1zinc protoporphyrinIBA
04/2016
1Genetic Markers (Genetic Marker)IBA
10/2015
1RetinoidsIBA
04/2013
1FenretinideIBA
04/2013
11-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA
09/2012
1X-Linked Inhibitor of Apoptosis ProteinIBA
05/2012
1LBW242IBA
05/2012

Therapy/Procedure

17Immunotherapy
01/2022 - 01/2003
15Therapeutics
01/2022 - 08/2002
5Drug Therapy (Chemotherapy)
06/2022 - 09/2002
2Stem Cell Transplantation
01/2021 - 01/2018
2Hematopoietic Stem Cell Transplantation
01/2021 - 08/2016
1Consolidation Chemotherapy
01/2022
1Regimen B
01/2020
1Neurosurgical Procedures
10/2019
1Enterostomy
08/2019
1Surgical Decompression
08/2019
1Aftercare (After-Treatment)
12/2018
1Salvage Therapy
08/2016